Dynamic Changes in Fourth Heart Sound in Type 2 Diabetes: Insights From Visualized Phonocardiography and SGLT2 Inhibitor Adjustment.

IF 0.7 Q3 MEDICINE, GENERAL & INTERNAL
Case Reports in Medicine Pub Date : 2025-08-11 eCollection Date: 2025-01-01 DOI:10.1155/carm/2871380
Kunimasa Yagi, Daisuke Chujo, Shimpei Ogawa, Shumpei Saito, Makoto Iwazawa, Taketsugu Tsuchiya, Shuichi Mizuta, Naohito Yamasaki, Takashi Muro
{"title":"Dynamic Changes in Fourth Heart Sound in Type 2 Diabetes: Insights From Visualized Phonocardiography and SGLT2 Inhibitor Adjustment.","authors":"Kunimasa Yagi, Daisuke Chujo, Shimpei Ogawa, Shumpei Saito, Makoto Iwazawa, Taketsugu Tsuchiya, Shuichi Mizuta, Naohito Yamasaki, Takashi Muro","doi":"10.1155/carm/2871380","DOIUrl":null,"url":null,"abstract":"<p><p>The fourth heart sound (S4) is an auscultatory marker of left ventricular diastolic dysfunction (LVDD). Additionally, S4 correlates with atrial function, which is typically impaired in patients with Type 2 diabetes (T2D) but can improve with sodium-glucose co-transporter-2 inhibitor (SGLT2i) therapy. This case report highlights the dynamic changes in S4 associated with modification of SGLT2i therapy. An 83-year-old male with T2D and LVDD, confirmed via echocardiography, was treated with SGLT2i therapy for 4 years for glycemic control. The therapy was discontinued in December 2023 because of increased nocturnal urination. Two months after discontinuation, the patient developed pronounced S4, accompanied by mild chest discomfort and worsening of evening leg edema. Resumption of SGLT2i therapy led to a marked reduction in S4 along with a remarkable improvement in chest discomfort and edema within 1 month. These findings were confirmed by visual phonocardiography. This case underscores the potential utility of dynamic S4 changes as a noninvasive indicator of SGLT2i therapy adjustment. These findings highlight the novel clinical application of S4 monitoring in mitigating heart failure progression in patients with T2D.</p>","PeriodicalId":9627,"journal":{"name":"Case Reports in Medicine","volume":"2025 ","pages":"2871380"},"PeriodicalIF":0.7000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360888/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/carm/2871380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

The fourth heart sound (S4) is an auscultatory marker of left ventricular diastolic dysfunction (LVDD). Additionally, S4 correlates with atrial function, which is typically impaired in patients with Type 2 diabetes (T2D) but can improve with sodium-glucose co-transporter-2 inhibitor (SGLT2i) therapy. This case report highlights the dynamic changes in S4 associated with modification of SGLT2i therapy. An 83-year-old male with T2D and LVDD, confirmed via echocardiography, was treated with SGLT2i therapy for 4 years for glycemic control. The therapy was discontinued in December 2023 because of increased nocturnal urination. Two months after discontinuation, the patient developed pronounced S4, accompanied by mild chest discomfort and worsening of evening leg edema. Resumption of SGLT2i therapy led to a marked reduction in S4 along with a remarkable improvement in chest discomfort and edema within 1 month. These findings were confirmed by visual phonocardiography. This case underscores the potential utility of dynamic S4 changes as a noninvasive indicator of SGLT2i therapy adjustment. These findings highlight the novel clinical application of S4 monitoring in mitigating heart failure progression in patients with T2D.

2型糖尿病第四心音的动态变化:来自可视化心音图和SGLT2抑制剂调整的见解
第四心音(S4)是左室舒张功能不全(LVDD)的听诊指标。此外,S4与心房功能相关,心房功能在2型糖尿病(T2D)患者中通常受损,但可以通过钠-葡萄糖共转运蛋白-2抑制剂(SGLT2i)治疗改善。本病例报告强调了与SGLT2i治疗修改相关的S4的动态变化。一名83岁男性,经超声心动图证实患有T2D和LVDD,接受SGLT2i治疗4年以控制血糖。由于夜间排尿增加,该治疗于2023年12月停止。停药2个月后,患者出现明显的S4,伴有轻度胸部不适和夜间腿部水肿加重。恢复SGLT2i治疗可在1个月内显著降低S4,并显著改善胸部不适和水肿。目视心音图证实了这些发现。该病例强调了动态S4变化作为SGLT2i治疗调整的无创指标的潜在效用。这些发现强调了S4监测在缓解T2D患者心力衰竭进展方面的新临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Case Reports in Medicine
Case Reports in Medicine MEDICINE, GENERAL & INTERNAL-
CiteScore
1.70
自引率
0.00%
发文量
53
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信